Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Roussaki-Schulze AV, Sinclair R, Bassukas ID, Thomas D, Neale A, Arora P, Caux F, Werth VP, Gourlay SG, Joly P; BELIEVE trial investigators. Murrell DF, et al. Among authors: zeeli t. Br J Dermatol. 2021 Oct;185(4):745-755. doi: 10.1111/bjd.20431. Epub 2021 Jun 15. Br J Dermatol. 2021. PMID: 33942286 Free PMC article. Clinical Trial.
Anterior Scleritis Associated with Pemphigus Vulgaris.
Zeeli T, Bar-Ilan E, Habot-Wilner Z, Sprecher E. Zeeli T, et al. Ocul Immunol Inflamm. 2019;27(3):497-498. doi: 10.1080/09273948.2017.1393547. Epub 2017 Nov 2. Ocul Immunol Inflamm. 2019. PMID: 29095065
Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, Gearhart L, Kapre A, Pordeli P, Chen DM; PEMPHIX Study Group. Werth VP, et al. N Engl J Med. 2021 Jun 17;384(24):2295-2305. doi: 10.1056/NEJMoa2028564. Epub 2021 May 19. N Engl J Med. 2021. PMID: 34097368 Clinical Trial.
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris.
Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Sinclair R, Neale A, Arora P, Sugerman PB, Shi G, Werth VP, Caux F, Joly P; BELIEVE Trial Investigators. Murrell DF, et al. Among authors: zeeli t. J Eur Acad Dermatol Venereol. 2022 Jun 10. doi: 10.1111/jdv.18318. Online ahead of print. J Eur Acad Dermatol Venereol. 2022. PMID: 35686647 No abstract available.
Coexistence of malignancies in pemphigus vulgaris.
Warshavsky K, Zeeli T, Mekiten O, Sprecher E, Silverman BG, Barzilai A, Baum S. Warshavsky K, et al. Among authors: zeeli t. Immunol Res. 2023 Oct;71(5):743-748. doi: 10.1007/s12026-023-09388-y. Epub 2023 May 4. Immunol Res. 2023. PMID: 37142890
28 results